BMRNBioMarin Pharmaceutical Inc.
$54.80+0.81% 1Y
$54.80
$49.6752 weeks$70.23
BMRN as reported
BioMarin Pharmaceutical Inc. reported $3.41B of revenue over the trailing twelve months, +11% on the year before. 11 reported series are charted on this page, each one as filed.
$3.41B
Revenue, trailing twelve months · to Q2 2026 · +11% against the twelve months before
- Net income
- $73M
Net income · −89% year on year · trailing twelve months to Q2 2026
- Free cash flow
- $738M
Free cash flow · +6.2% year on year · trailing twelve months to Q2 2026
- Operating margin
- 4.3%
Operating margin · trailing twelve months to Q2 2026
Details›
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $3.41B | +11% | Q2 2026 |
| Net income | $73M | −89% | Q2 2026 |
| EPS | $0.37 | −89% | Q2 2026 |
| Gross margin | 76% | n/a | Q2 2026 |
| Operating margin | 4.3% | n/a | Q2 2026 |
| Net margin | 2.3% | n/a | Q2 2026 |
| ROE | 5.0% | n/a | Q2 2026 |
| ROA | 3.8% | n/a | Q2 2026 |
| ROIC | 5.3% | n/a | Q2 2026 |
| Free cash flow | $738M | +6.2% | Q2 2026 |
| P/E | 148 | n/a | today |
Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.
BioMarin Pharmaceutical Inc. (BMRN) · Revenue and profitRevenue and profitBioMarin Pharmaceutical Inc. (BMRN)
RevenueNet incomeTrailing twelve months
Powered byryufin.com
